Introduction: The Unmet Need in Advanced Soft-Tissue Sarcoma
Soft-tissue sarcomas (STS) represent a highly heterogeneous group of mesenchymal malignancies, comprising more than 50 distinct histological subtypes. While localized disease is often manageable through surgical resection and radiotherapy, advanced or metastatic STS remains a formidable clinical challenge. For decades, the standard first-line systemic therapy has revolved around anthracycline-based regimens, specifically doxorubicin, either as a monotherapy or in combination with ifosfamide. Despite these efforts, the median overall survival for patients with metastatic disease has historically lingered between 12 and 18 months, with objective response rates (ORR) often failing to exceed 20 percent in unselected populations.
The search for more effective first-line strategies has led to the exploration of multi-targeted therapies. Angiogenesis plays a critical role in the pathogenesis and progression of several sarcoma subtypes. Anlotinib, a potent oral multi-targeted tyrosine kinase inhibitor (TKI), has shown significant activity by inhibiting the vascular endothelial growth factor receptors (VEGFR 1-3), fibroblast growth factor receptors (FGFR 1-4), platelet-derived growth factor receptors (PDGFR alpha and beta), and c-Kit. Previously approved in later-line settings, the integration of anlotinib into the first-line treatment paradigm, combined with traditional cytotoxic chemotherapy, represents a logical evolution in sarcoma care.